secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0001104659-25-062722
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma's YUPELRI approved by China's NMPA; $7.5M milestone triggered
--------------------------------------------------------------------------------

- China's NMPA approved YUPELRI (revefenacin) as first once-daily nebulized LAMA for COPD maintenance.
- Approval triggers $7.5M milestone from Viatris, expected Q3 2025; eligible for up to $37.5M in sales milestones and 14-20% tiered royalties.
- Viatris responsible for all development/commercialization; Theravance incurs no commercial costs in China.
- Theravance cash $131M (Mar 31), plus $225M from TRELEGY royalty sale and up to $150M near-term TRELEGY milestones.
- Theravance nearing completion of enrollment in open-label portion of CYPRESS study of ampreloxetine for nOH in MSA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925062722/0001104659-25-062722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925062722/tm2519052d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-062722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer